METHOD FOR PREDICTION OF PRIMARY AND SECONDARY VACCINAL FAILURES AT VACCINATION AGAINST VIRUSES OF RUBEOLA, RUBELLA AND EPIDEMIC HEPATITIS IN CHILDREN USING PRIORIX VACCINE AND METHOD OF INDIVIDUAL APPROACH TO CORRECTION OF VACCINAL FAILURES Russian patent published in 2016 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to immunology, and is intended for individual prediction of vaccination efficacy against viruses of rubeola, rubella and an epidemic parotitis using Priorix vaccine. For the prediction of primary vaccinal failures the amount of specific IgG for each of three vaccine viruses one month after vaccination is calculated by formulas: [IgG rubeola]=-2.25+0.031[CD3⁺%]+0.064[CD3^-CD16/56⁺%]+0.244[TNF-α]-0.417[IgM]+0.042[IgG]+0.008[lymphocytes%]; [IgG rubella]=66.443-5.412[IgG]+23.834[IgM]; [IgG parotitis]=-9.537-3.812[CD3⁺8⁺%]-0.041[CD3^-CD16/56⁺]+5.105[CD3^-CD16/56⁺%]+2.374[CD3⁺%]-1.363[CD3⁺4⁺%], where [CD3⁺%] is a percentage of CD3⁺ lymphocytes in peripheral blood, [CD3^-CD16/56⁺%] - percentage of NK-lymphocytes in peripheral blood, [CD3^-CD16/56⁺] - absolute number of NK-lymphocytes in mm³ peripheral blood, [TNF-α] - tumor necrosis factor level α in blood serum, [IgM] - level of common IgM in blood serum, [IgG] - level of common IgG in blood serum, [lymphocytes%] - percentage of lymphocytes in peripheral blood, [CD3⁺8⁺%] - percentage of cytotoxic lymphocytes in peripheral blood, [CD3⁺4⁺%] - percentage of helper cells in peripheral blood. Protective antibody level for virus of rubeola is considered at the value [IgG rubeola] exceeding 0.25 Iu/ml; for viruses of rubella at the value [IgG rubella] exceeding 35 Iu/ml; for viruses of epidemic parotitis at the value [IgG parotitis] exceeding 25 Iu/ml, and at the absence of protective antibody level the primary vaccinal failure is predicted. Secondary vaccinal failure in response to epidemic parotitis virus is predicted, if the value of common IgA is less than 0.45 mg/ml, interleukin-4 level is less than 1.5 pg/ml and TNF-α is less than 0.6 pg/ml; secondary vaccinal failure in response to rubeola virus is predicted, if the value of interleukin-4 is less than 2.0 pg/ml and lymphocyte number in mm³ blood is less than 5,000. Group of inventions also involves a method of individual approach to correction of vaccinal failures.

EFFECT: using this group of inventions enables to perform individual approach to the vaccination program for children in a risk group using the method for prediction of primary or secondary vaccinal failures.

2 cl, 4 dwg